Dixon Technologies' Q2FY24 Financial Performance Review

In this financial performance review, we delve into the results of Dixon Technologies for the second quarter of fiscal year 2024. and analyze key metrics, including revenue, expenses, net profit, and margin.

 

ParticularsQ2FY23(Y-o-Y) % changeQ1FY24(Q-o-Q) % changeQ2FY24
Total Income (₹crs.)2,926.21-28.881,516.5237.232,081.05
Expenses (₹crs.)3,766.5427.383,187.3450.534,797.83
Net Profit (₹crs.)77.146.9967.1968.72113.36
Margin (%)2.642.814.431.025.45

 

REVENUE: 
Dixon Technologies reported a total income of ₹2,081.05 crores for Q2FY24, marking a substantial improvement of 37.23% sequentially. However, when compared to the same quarter in the previous fiscal year, Q2FY23, the company experienced a decline of -28.88%.

 

EXPENSES: 
Expenses for Dixon Technologies in Q2FY24 amounted to ₹4,797.83 crores, showcasing a significant increase of 50.53% compared to the preceding quarter. On a year-on-year basis, the company's expenses increased by 27.38%.

 

NET PROFIT: 
The net profit of Dixon Technologies for Q2FY24 was ₹113.36 crores, reflecting a remarkable growth of 68.72% sequentially. On a year-on-year basis, the company demonstrated a substantial 46.99% increase in net profit.

 

MARGINS: 
Dixon Technologies' margin in Q2FY24 was 5.45%, indicating an impressive 1.02% increase compared to the preceding quarter. Year-on-year, the company exhibited a positive margin shift, with a 2.81% increase.

 

In conclusion, Dixon Technologies' financial performance in Q2FY24 stands out with significant improvements in revenue, net profit, and margins. Despite a challenging year-on-year comparison, the company rebounded impressively, driven by what the government push of Make in India and market positioning. 

 

Stay tuned for more detailed updates on Dixon Technologies' financial performance in the coming quarters.
 

Top stories
Company

Delta Corp Q1 PAT Declines 68% YoY to Rs 22 crore in FY25

4 mins read . 13 Jul 2024 . 09:30 AM

Company

Zydus Life Gets USFDA Nod for Heart Failure Drug

3 mins read . 13 Jul 2024 . 09:23 AM

Company

RVNL Spurts 10% on Bagging Multiple Orders Worth Rs 390 Cr

4 mins read . 13 Jul 2024 . 09:18 AM

Related Blogs
blog-logo

Share Market

blog-logo

12 mins read . 12 Jul 2024

Ritesh Agarwal: The OYO Founder’s Success Story

  • 0 people read
blog-logo

Share Market

blog-logo

15 mins read . 08 Jul 2024

Best Oil & Gas Stocks in India

  • 0 people read
Kickstart your equities journey today You've got this
By submitting this I agree to the terms & conditions